← Leaderboards
Martin Golkowski
University Of Washington
$1,310,500
Attributed
$1,310,500
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $385K · FY2020–25$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,310,500 · 2
By mechanism
R35$1,155,000 · 1
R03$155,500 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Washington
Same institution · by research overlap
- Dustin J Maly$15,468,910
- Diana J Wilkie$16,363,356
- David R Sherman$26,094,329
- Junko Oshima$3,761,782
- George M. Martin$5,470,369
Others in their field
Other Emerging Leaders on “Pathway Interactions”
- April Brinkoetter · Hungry Heart Media, Inc.$59,802,265
- Kevin Urdahl · Seattle Children'S Hospital$47,227,116
- Urs Ochsner · Crestone, Inc.$38,569,476
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Nader Fotouhi · Global Alliance For Tb Drug Development$28,468,137
- Jeffrey Glenn · Stanford University$26,017,226
Research focus
Pathway InteractionsCellsProteinsDrug ResistanceNeoplasm MetastasisDrug TargetingPhosphotransferasesProtein KinaseHuman DiseaseDisease ProgressionGenomicsBiologyAutomobile DrivingChemoproteomicsImmuneCell PhysiologyCreativenessBiological ProcessFosteringCell NucleusCrosslinkDisease PhenotypeEpigenomicsChromatin
Grant awards (4)
Integrated mass spectrometry-based chemoproteomic and genomic technologies for studying dynamic kinase interactomes$385,000
R35 · FY2025 · GM · contact PI
Integrated mass spectrometry-based chemoproteomic and genomic technologies for studying dynamic kinase interactomes$385,000
R35 · FY2024 · GM · contact PI
Integrated mass spectrometry-based chemoproteomic and genomic technologies for studying dynamic kinase interactomes$385,000
R35 · FY2023 · GM · contact PI
Targeting understudied kinases in cancer cell plasticity and drug resistance$155,500
R03 · FY2020 · TR · contact PI